Sanofi
In Brief This Week: Cullinan Oncology, Aileron Therapeutics, Sanofi, Exscientia
News items for the week of Jan. 3, 2022.
Sanofi Makes $180M Equity Investment in Owkin, Inks AI-Based Precision Oncology Collaboration
Sanofi will tap into Owkin's network and AI-based discovery platform to develop treatments for NSCLC, TNBC, mesothelioma, and multiple myeloma.
Agilent Technologies Obtains CE Mark for Expanded Use of PD-L1 CDx in NSCLC
The firm said that the expanded use for its CDx will enable European pathologists to identify patients with NSCLC who may be eligible for treatment with cemiplimab.
European Commission Approves Regeneron, Sanofi's Libtayo for First-Line NSCLC
Based on the results of the EMPOWER-Lung 1 trial, the regulators approved the drug in advanced NSCLC patients with high PD-L1 expression.
EMA's CHMP Issues Positive Opinion on Regeneron, Sanofi's Libtayo in NSCLC
The committee recommended approval for the anti-PD-1 drug in first-line NSCLC patients who have PD-L1 expression in at least 50 percent of tumor cells.